Which children with nephrotic syndrome benefit from cyclosporin A or cyclophosphamide?
Coulthard
Malcolm G
MG
D049109:Cell Proliferation; D002648:Child; D003520:Cyclophosphamide / Q000008:administration & dosage* / Q000627:therapeutic use*; D016572:Cyclosporine / Q000009:adverse effects / Q000627:therapeutic use*; D005920:Glomerular Mesangium / Q000473:pathology; D005923:Glomerulosclerosis, Focal Segmental / Q000188:drug therapy / Q000473:pathology; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D050527:Mesangial Cells / Q000473:pathology; D009404:Nephrotic Syndrome / Q000188:drug therapy*; D020551:Pulse Therapy, Drug; D016032:Randomized Controlled Trials as Topic
D007166:Immunosuppressive Agents; D016572:Cyclosporine; D003520:Cyclophosphamide